Esperion Therapeutics | ESPR - Stock


Esperion Therapeutics reported $104.21M in Stock for its fiscal quarter ending in March of 2026.





Stock Change Date
AbbVie USD 5.05B 98M Mar/2026
Alnylam Pharmaceuticals USD 200.15M 117.43M Mar/2026
Amarin USD 183.58M 12.32M Mar/2026
Amgen USD 6.19B 39M Mar/2026
Biogen USD 1.95B 219.1M Mar/2026
BioMarin Pharmaceutical USD 1.27B 25.66M Mar/2026
Cipla INR 61.6B 5.18B Sep/2025
CSL USD 6.47B 327M Jun/2025
Daiichi Sankyo JPY 608.55B 93.64B Sep/2025
Eli Lilly USD 14.53B 785M Mar/2026
Esperion Therapeutics USD 104.21M 915K Mar/2026
Geron USD 133.29M 16.65M Mar/2026
Grifols EUR 3.56B 63.19M Dec/2024
Halozyme Therapeutics USD 155.47M 21.01M Mar/2026
Heron Therapeutics USD 54.57M 2.33M Dec/2022
Ionis Pharmaceuticals USD 5.56M 4.49M Mar/2026
Merck USD 6.48B 179M Mar/2026
Moderna USD 146M 7M Mar/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Pfizer USD 10.67B 13M Mar/2026
PTC Therapeutics USD 75.57M 4.08M Mar/2026
Puma Biotechnology USD 9.48M 885K Sep/2025
Regeneron Pharmaceuticals USD 3.1B 97.2M Mar/2026
Sanofi EUR 22.69B 1.81B Dec/2025
Sarepta Therapeutics USD 1B 86.37M Mar/2026
United Therapeutics USD 178.3M 4.8M Mar/2026
Vanda Pharmaceuticals USD 1.85M 190K Dec/2025